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Abstract 
The use of marijuana as a medicinal agent is an old practice in many parts of the world. In recent decades 
it has gained increased attention of the general public and of the medical profession. Ten states and 
Canada have legalized medical marijuana; physicians prescribe it for nausea and vomiting in patients 
receiving cancer chemotherapy. They also prescribe it for appetite loss and wasting in patients with 
acquired immunodeficiency syndrome. Controversies exist about its use in the treatment of glaucoma, 
spasticity or chronic intractable pain.  Though state governments have passed laws authorizing physicians 
to prescribe marijuana, the federal government contends that the drug is a Schedule I agent with no 
medicinal use, a high potential for abuse and no accepted safety for use in medically-supervised 
treatment. There are legal issues regarding its use as a medicinal agent, and the United States Supreme 
Court has provided rulings on these matters.  This paper will explore those controversies, the history of 
medical marijuana and the implications for its future use as a therapeutic agent in this country. 
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Introduction 
The medical use of marijuana is not new.  For 
centuries people have believed that the hemp 
plant Cannabis sativa has healing properties. It 
is one of the oldest plants that we know, and 
thousands of years ago people used it for its 
medicinal properties. In 1753, Linnaeus 
classified Cannabis as having only one species. 
He wrote about Cannabis sativa which is the 
most well-known species. It is this latter species 
from which we derive marijuana. It is 
conceivable that some cultures grew the hemp 
plant for food. Research also indicates that six 
thousand years ago people used it for fiber to 
make cloth, ropes, fishing nets and paper. The 
plant originated from Asia. Archaeologists have 
located samples of hemp more than three 
thousand years old in Egypt. People considered 
it to be a grain, and they extracted oil from the 
seeds. Other grains at that time were millet, rice 
barley and soybeans. Between 110AD and 
207AD, physicians boiled hemp with wine to 
create an anesthetic for use during major 
surgery. Chinese physicians utilized hemp as a 
therapeutic agent too, but because of the plant’s 
mind-altering qualities abandoned its use.  
Nevertheless, physicians have used the plant for 
fever, arthritic pain and treatment of pus-
forming infections. Some have used marijuana 
for relaxation and to enhance their social or 
sexual lives or to have religious experiences. 
Soaking hemp in rum appears to bring relief 
from arthritic and other musculoskeletal aches 
and pain. In 1842, marijuana became part of 
Western medicine, but 100 years later the United 
States Pharmacopoeia ceased to list it.  Many 
twentieth century investigators have said that 
there may be additional species of the plant. 
Examples of those species are Cannabis indica 
and Cannabis ruderalis. Today the plant grows 
in the United States, the Himalaya Mountains, 
Canada and Africa. The only legal supply in the 
United States is a National Institute on Drug 
Abuse operated farm in Mississippi (Vastag, 
2003).  Illegal use of the drug is its most 
common employment (Walker, 1997). People 
use marijuana more today than any other illicit 
drug (Watson, 2000). 
 
Medicinal Properties of Hemp 
The cannabinoids are the psychoactive 
chemicals in the hemp plant. Specifically, 9-
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tetrahydrocannabinol (THC) has antiemetic, 
analgesic, antianxiety, sedative and appetite-
stimulating properties (Kane, 2001; Watson, 
2000). Identification of these chemicals occurred 
during the 1960s. In 1996, the California 
Compassionate Use Act enabled people with 
certain medical conditions to grow and use 
marijuana with a physician’s recommendation.  
Those conditions included cancer, multiple 
sclerosis, acquired immunodeficiency syndrome, 
glaucoma and chronic intractable pain. Several 
states have passed similar laws. The Canadian 
government proposed similar laws in 2001. The 
United States Congress has contended that 
marijuana is an illegal drug with no appropriate 
medical use. The US Food and Drug 
Administration has approved dronabinol, a 
synthetic form of THC, to treat nausea and 
vomiting which results from cancer 
chemotherapy and for AIDS wasting (Kane, 
2001; Vastag, 2003). 
 
For human immunodeficiency virus infection 
(HIV) some have used marijuana to stimulate 
the appetite in wasting patients (Kane, 2001; 
Watson, 2000). In 1992 the Food and Drug 
Administration approved the use of synthetic 
dronabinol for the treatment of appetite loss in 
patients with acquired immunodeficiency 
syndrome. Dronabinol is an oral form of the 
psychoactive component of marijuana (Vastag, 
2003). Administering oral dronabinol to treat 
nausea and vomiting from cancer chemotherapy 
is not always successful as the patient may 
regurgitate the tablets. Also oral dronabinol can 
take up to an hour to render its effect.  
Therefore, some have recommended smoked 
marijuana, which elicits results in only a few 
minutes, to treat nausea and vomiting in cancer 
patients (Vastag, 2003). There may be benefit in 
the treatment of peripheral neuropathy in these 
patients.  Drugs, including protease inhibitors 
which physicians prescribe to treat human 
immunodeficiency virus, undergo the same 
metabolism method as does marijuana.  This 
gives rise to the question as to whether 
adjustment in protease inhibitor dosage will be 
necessary in marijuana smokers who are HIV 
positive (Kane, 2001; Abrams, 2003). Most 
scientists believe that THC is the chemical in 
marijuana which gives hemp its effects. Others, 
however, have stated that natural hemp leaf has 
many chemicals, and one must have the natural 
product in order to experience those 
psychoactive or other effects. We do know that 
cannabinoids affect movement control, balance, 
coordination, sensation of pleasure and 
perception of pain.  These chemicals also affect 
learning functions and memory. Cannabinoid 
brain receptors exist in the cerebellum, the 
amygdala, the hippocampus, the hypothalamus 
and basal ganglia (Kane, 2001; Watson, 2000). 
Cannabinoids and opiates have similar signaling 
pathways in the human nervous system (Kane, 
2001). 
 
Administering tetrahydrocannabinol takes thirty 
to sixty minutes to bring the effect of the drug. 
Smoking marijuana will yield an effect in three 
to five minutes or sooner (Kane, 2001; Vastag, 
2003). The pharmaceutical industry has 
considered giving the drug by transdermal patch, 
rectal suppository, nasal sprays or smokeless 
inhaler. Researchers in the United Kingdom 
have produced hybridized or cross-breeding 
forms of marijuana. The latter products have 
higher concentrations of tetrahydrocannabinol 
than does the naturally-grown plant (Kane, 
2001). 
 
Objections to Medical Marijuana 
Arguments against the medicinal use of 
marijuana largely consider the drug’s harmful 
effects on the body. Those effects include the 
potential for addiction and its mind-altering 
properties. Marijuana damages the respiratory 
system.  When smoking marijuana, it is difficult 
to measure what dose of the drug one receives 
(Watson, 2000; Kane, 2001). Tolerance 
develops with continued use of marijuana, and 
one will require larger doses each time to obtain 
the effects. Physicians also find it difficult to 
monitor pain relief in light of the euphoria or 
“high” which smokers experience from the 
drug’s use. There are other established 
medications to treat pain, and their existence 
makes many scientists hesitant to believe that 
using marijuana for pain management is 
advantageous (Kane, 2001). 
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Marijuana and the Court 
The United States Supreme Court has ruled that 
taking marijuana for medicinal purposes can 
prompt federal prosecution regardless of 
individual state law. The federal government can 
arrest and prosecute patients who use marijuana 
and those who supply the drug. The United 
States Inspector General has also brought action 
against physicians who prescribe marijuana and 
excluded them from being Medicare providers.  
The regulation of interstate commerce of illegal 
drugs is the authority of the federal government 
under the Controlled Substances Act. The 
following states have legalized marijuana: 
California, Alaska, Colorado, Hawaii, Maine, 
Montana, Nevada, Oregon, Vermont and 
Washington (Okie, 2005; Vastag, 2003).  
Canada legalized marijuana in 2001; the plant 
grows there in an underground mine in Manitoba 
(Vastag, 2003). Federal agents visited San 
Francisco’s medical marijuana dispensaries after 
the Supreme Court ruling. In California there are 
approximately 100,000 people who use medical 
marijuana. The United States District Court for 
the Northern District of California ruled that 
physicians who prescribe marijuana have 
protection from prosecution. The requirement 
for protection is that the physician cannot help 
the patient get the drug.  Nevertheless, there has 
been objection from some residents of California 
to the use of medical marijuana.  California state 
officials have considered a program to register 
patients who use medical marijuana; however, 
concern about federal prosecution has caused 
those state officials to withhold the development 
of a patient registration program (Okie, 2005). 
 
The United States Supreme Court has ruled in 
Gonzalez v. Raich that federal law enforcement 
authorities can prosecute patients who use 
physician-prescribed marijuana. This is true 
even if state law authorizes the physician to 
prescribe the drug. Seriously ill patients in 
California have access to marijuana for their 
illness; this is a result of the California 
Compassionate Use Act of 1996. This act 
protects prescribing physicians from prosecution 
(Gostin, 2005). Physician prescribing of 
marijuana becomes a commerce clause matter 
before the United States Supreme Court (Annas, 
2005). The conflict between the federal 
Controlled Act and state law has resulted in the 
Raich suit. Angel Raich has an inoperable brain 
tumor, and federal agents have destroyed her 
cannabis plants. Marijuana is a schedule I drug 
which includes those agents that have no 
medicinal use, a high potential for abuse and no 
accepted safety for use in treatment which is 
medically supervised.  Heroin and lysergic acid 
diethylamide are also Schedule I substances.  
Unless one prescribes marijuana in a Food and 
Drug Administration approved research study, 
marijuana is a criminally prohibited drug.  
President Nixon initiated the federal Controlled 
Substances Act in 1970 with his “war on drugs” 
(Gostin, 2005). 
 
Federalism means that individual states place 
some powers in the hands in the hands of a 
national government. Interstate commerce and 
foreign affairs are examples of those powers 
which the national government regulates. It is 
controversial how many powers the states will 
delegate to the federal government (Gostin, 
2005). Individual states have police powers and 
sovereign authority to protect the safety, health 
and welfare of its residents. Congress regulates 
commerce among the states; it also regulates 
commerce with foreign nations and with Indian 
tribes. Other areas which Congress regulates 
include currency, the postal service and 
patenting. The United States Constitution 
determines the government’s authority. 
Individual states have had authority to regulate 
areas which Congress does not supervise; this 
latter authority of the states existed before and 
after the writing of the United States 
Constitution (Annas, 2005). The Drug 
Enforcement Administration, the National 
Institute on Drug Abuse and the Food and Drug 
Administration are the three federal agencies 
which assume responsibility for medical 
marijuana. Medical marijuana is only one 
example of an individual state creating a 
courageous social experiment. Oregon’s 
physician-assisted suicide is another case of an 
individual state bringing innovative ideas to the 
country (Gostin, 2005). 
 
The 1999 Institute of Medicine Report 
The White House Office of National Drug 
Control Policy requested that the Institute of 
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Medicine evaluate the possible benefits and uses 
of marijuana as a therapeutic agent (Watson, 
2000). There is evidence that this drug can 
produce analgesia and that it can relieve the 
nausea and vomiting resulting from cancer 
chemotherapy. One must recognize, however, 
that there are other traditional agents that 
physicians successfully utilize to treat pain or to 
treat nausea and vomiting. These latter agents 
are as effective as marijuana. Marijuana is 
beneficial in treating the wasting, cachexia, and 
weight loss in patients with acquired 
immunodeficiency virus syndrome. Some have 
contended that cannabinoids relieve spasticity; 
however, the evidence for this benefit is not 
clear. The 1999 Institute of Medicine report does 
not strongly recommend the use of marijuana for 
the treatment of Parkinson’s Disease or other 
movement disorders. Marijuana has an 
antianxiety effect, and the presumed benefit 
which some describe in treating movement 
disorders may be relief of anxiety rather than 
direct effect on the basal ganglia of the brain.  
The basal ganglia of the brain are the anatomic 
focus of many movement disorders such as 
Parkinson’s Disease. The Institute of Medicine 
also does not recommend further research on use 
of cannabinoids to treat seizures. The 
hippocampus and amygdala of the brain 
participate in partial seizures, and there are 
cannabinoid receptors in these parts of the brain. 
This has enabled some to conclude that 
marijuana will be useful in treating epilepsy, but 
the Institute of Medicine investigation does not 
support this. There are also many agents which 
are not controlled substances available to 
successfully control epileptic seizures. The same 
is true when using marijuana to treat glaucoma. 
Although there is some transient benefit in 
administering marijuana to glaucoma patients, 
the more familiar pharmacologic agents are 
equally beneficial and much easier to monitor 
for side effects and dosage requirements.  When 
using smoked marijuana, it is difficult to 
monitor the dose that one receives (Kane, 2001; 
Watson, 2000). Traditional drugs to treat 
seizures or glaucoma are easily dispensed and 
measured in the amount that one gives to the 
patient (Watson, 2000). The hemp plant will 
have varying amounts of the drug in each plant, 
and this makes it difficult to know how much of 
the drug one administers to the patient. 
 
Smoking marijuana irritates the lining of the 
respiratory tract and increases the risk of cancer. 
Smoking it during pregnancy can be detrimental 
to the fetus. The Institute of Medicine 
recommends that use of marijuana occur only in 
a controlled clinical research trial with 
Institutional Review Board approval and for a 
period not more than six months. The Institute of 
Medicine conclusion is that cannabinoids may 
be effective in treating chronic pain, nausea and 
vomiting and for appetite stimulation (Watson, 
2000). 
 
Conclusion 
Medical marijuana has gained increased 
attention of the medical community and of the 
general public. The medicinal value of this drug 
is well-known throughout history, and the best 
researchers in the area acknowledge marijuana’s 
effects. There are, however, traditional drugs 
which can effectively treat many of the same 
conditions for which some have used marijuana, 
and monitoring the dose of marijuana may be 
difficult. More research is necessary to further 
delineate the benefit of legalizing the hemp plant 
in the United States and in other countries. 
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